{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T22:38:53Z","timestamp":1772491133751,"version":"3.50.1"},"reference-count":85,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/publications.ersnet.org\/user-licence"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["LA\/P\/0064\/2020"],"award-info":[{"award-number":["LA\/P\/0064\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04750\/2020"],"award-info":[{"award-number":["UIDB\/04750\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2025,9,2]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nontuberculous mycobacteria (NTM) are associated with chronic and challenging infections, particularly pulmonary disease (NTM-PD). While clinical guidelines provide treatment recommendations for the most common disease-causing species, they offer limited guidance on managing treatment failures. This study aims to develop a consensus-based decision-making framework for addressing treatment failure in NTM-PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A panel of 16 international experts used the e-Delphi method to address gaps in NTM-PD management. Initial statements were derived from an open-ended questionnaire, supported by a prior systematic review. Iterative rounds of expert evaluation were conducted until a consensus was reached on treatment failure definitions, decision-making criteria, therapeutic strategies and supportive care measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Consensus defined treatment failure as the absence of culture conversion after 6\u2005months of appropriate antimycobacterial therapy, while clinical and radiological deterioration were considered additional but non-mandatory criteria. Treatment intensification or de-escalation decisions were based on patient preferences, clinical status, comorbidities, disease severity, antibiotic tolerance, resistance patterns and previous treatment history. Treatment intensification highlighted the necessity for personalised multidrug antibiotic regimens. De-escalation strategies focus on delivering optimal, patient-centred supportive care while minimising pharmacological adverse effects, by opting for simplified antibiotic regimens, intermittent antibiotic courses for symptomatic control or the cessation of antimicrobial therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study offers a structured approach to managing treatment failure in NTM-PD, addressing patient selection, treatment intensification, de-escalation and supportive care, while championing individualised strategies. Future research should concentrate on validating predictive factors for treatment response, refining therapeutic regimens and investigating host-directed therapies to enhance patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.00400-2025","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:00:22Z","timestamp":1762452022000},"page":"2500400","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Consensus on the management of refractory nontuberculous mycobacterial pulmonary disease"],"prefix":"10.1183","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4514-6110","authenticated-orcid":false,"given":"Diana","family":"Moreira-Sousa","sequence":"first","affiliation":[]},{"given":"Beatriz","family":"Martins","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7643-8963","authenticated-orcid":false,"given":"Ana","family":"Aguiar","sequence":"additional","affiliation":[]},{"given":"Marina","family":"Pinheiro","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5638-9260","authenticated-orcid":false,"given":"Onno","family":"Akkerman","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5243-5394","authenticated-orcid":false,"given":"Timothy R.","family":"Aksamit","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-4531","authenticated-orcid":false,"given":"Stefano","family":"Aliberti","sequence":"additional","affiliation":[]},{"given":"Claire","family":"Andrejak","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3324-926X","authenticated-orcid":false,"given":"Charles L.","family":"Daley","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-2003","authenticated-orcid":false,"given":"Jakko","family":"van Ingen","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9691-4741","authenticated-orcid":false,"given":"Christoph","family":"Lange","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7501-4448","authenticated-orcid":false,"given":"Marc","family":"Lipman","sequence":"additional","affiliation":[]},{"given":"Michael R.","family":"Loebinger","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0171-764X","authenticated-orcid":false,"given":"Mateja","family":"Jankovic Makek","sequence":"additional","affiliation":[]},{"given":"Kozo","family":"Morimoto","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0686-171X","authenticated-orcid":false,"given":"Rachel M.","family":"Thomson","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3271-5815","authenticated-orcid":false,"given":"Dirk","family":"Wagner","sequence":"additional","affiliation":[]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[]},{"given":"Jae-Joon","family":"Yim","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-3099","authenticated-orcid":false,"given":"Raquel","family":"Duarte","sequence":"additional","affiliation":[]}],"member":"81","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"2026010801351191000_67.1.2500400.1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00149212"},{"key":"2026010801351191000_67.1.2500400.2","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1055\/s-0038-1660864","article-title":"Geographic distribution of nontuberculous mycobacteria isolated from clinical specimens: a systematic review","volume":"39","author":"Zweijpfenning","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"key":"2026010801351191000_67.1.2500400.3","doi-asserted-by":"publisher","DOI":"10.1038\/srep45258"},{"key":"2026010801351191000_67.1.2500400.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.10.013"},{"key":"2026010801351191000_67.1.2500400.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2023.08.012"},{"key":"2026010801351191000_67.1.2500400.6","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac649"},{"key":"2026010801351191000_67.1.2500400.7","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1080\/17476348.2021.1987891","article-title":"Nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex \u2013 disease burden, unmet needs, and advances in treatment developments","volume":"15","author":"van Ingen","year":"2021","journal-title":"Exp Rev Respir Med"},{"key":"2026010801351191000_67.1.2500400.8","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0433"},{"key":"2026010801351191000_67.1.2500400.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.06.005"},{"key":"2026010801351191000_67.1.2500400.10","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3113-x"},{"key":"2026010801351191000_67.1.2500400.11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix517"},{"key":"2026010801351191000_67.1.2500400.12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01991-2018"},{"key":"2026010801351191000_67.1.2500400.13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01206-17"},{"key":"2026010801351191000_67.1.2500400.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.01.024"},{"key":"2026010801351191000_67.1.2500400.15","doi-asserted-by":"crossref","first-page":"105899","DOI":"10.1016\/j.rmed.2020.105899","article-title":"Real-life evaluation of clinical outcomes in patients undergoing treatment for non-tuberculous mycobacteria lung disease: a ten-year cohort study","volume":"164","author":"Aliberti","year":"2020","journal-title":"Respir Med"},{"key":"2026010801351191000_67.1.2500400.16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00535-2020"},{"key":"2026010801351191000_67.1.2500400.17","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-209729"},{"key":"2026010801351191000_67.1.2500400.18","doi-asserted-by":"crossref","unstructured":"Moreira-Sousa D , Martins B , Aguiar A , et al. Management of nontuberculous mycobacterial pulmonary disease refractory to guideline-based therapy: a systematic review. medRxiv 2025; preprint. doi:10.1101\/2025.06.23.25330100","DOI":"10.1101\/2025.06.23.25330100"},{"key":"2026010801351191000_67.1.2500400.19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00170-2018"},{"key":"2026010801351191000_67.1.2500400.20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1318OC"},{"key":"2026010801351191000_67.1.2500400.21","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-1165-3"},{"key":"2026010801351191000_67.1.2500400.22","doi-asserted-by":"crossref","first-page":"106549","DOI":"10.1016\/j.rmed.2021.106549","article-title":"Radiographic severity and treatment outcome of Mycobacterium abscessus complex pulmonary disease","volume":"187","author":"Park","year":"2021","journal-title":"Respir Med"},{"key":"2026010801351191000_67.1.2500400.23","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3390\/antibiotics11121720","article-title":"Epidemiology, outcomes and tolerability of protracted treatment of nontuberculous mycobacterial infections at a community teaching hospital in the southeastern United States","volume":"11","author":"Tsai","year":"2022","journal-title":"Antibiotics"},{"key":"2026010801351191000_67.1.2500400.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2022.03.026"},{"key":"2026010801351191000_67.1.2500400.25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw724"},{"key":"2026010801351191000_67.1.2500400.26","doi-asserted-by":"crossref","first-page":"ofab215","DOI":"10.1093\/ofid\/ofab215","article-title":"Impact of susceptibility to injectable antibiotics on the treatment outcomes of Mycobacterium abscessus pulmonary disease","volume":"8","author":"Park","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026010801351191000_67.1.2500400.27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232714"},{"key":"2026010801351191000_67.1.2500400.28","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.chest.2023.08.025","article-title":"Outcomes of intermittent multidrug IV therapy for refractory Mycobacterium abscessus pulmonary disease","volume":"165","author":"Im","year":"2023","journal-title":"Chest"},{"key":"2026010801351191000_67.1.2500400.29","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-2764"},{"key":"2026010801351191000_67.1.2500400.30","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku062"},{"key":"2026010801351191000_67.1.2500400.31","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2017.04.175","article-title":"Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial infection","volume":"152","author":"Martiniano","year":"2017","journal-title":"Chest"},{"key":"2026010801351191000_67.1.2500400.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2014.05.010"},{"key":"2026010801351191000_67.1.2500400.33","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202008-925OC"},{"key":"2026010801351191000_67.1.2500400.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.05.036"},{"key":"2026010801351191000_67.1.2500400.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.03.070"},{"key":"2026010801351191000_67.1.2500400.36","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad335"},{"key":"2026010801351191000_67.1.2500400.37","doi-asserted-by":"publisher","DOI":"10.1016\/0003-4975(96)00534-6"},{"key":"2026010801351191000_67.1.2500400.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(98)00373-7"},{"key":"2026010801351191000_67.1.2500400.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(01)03245-3"},{"key":"2026010801351191000_67.1.2500400.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2013.03.008"},{"key":"2026010801351191000_67.1.2500400.41","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-0823-1"},{"key":"2026010801351191000_67.1.2500400.42","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-021-01679-0"},{"key":"2026010801351191000_67.1.2500400.43","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac453"},{"key":"2026010801351191000_67.1.2500400.44","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00330-024-10987-y","article-title":"Evaluation of treatment response with serial CT in patients with non-tuberculous mycobacterial pulmonary disease","volume":"35","author":"Dettmer","year":"2024","journal-title":"Eur Radiol"},{"key":"2026010801351191000_67.1.2500400.45","doi-asserted-by":"crossref","first-page":"1468383","DOI":"10.3389\/fmicb.2024.1468383","article-title":"Drug\u2013drug interactions in the management of non-tuberculous mycobacterial infections","volume":"15","author":"Takeda","year":"2024","journal-title":"Front Microbiol"},{"key":"2026010801351191000_67.1.2500400.46","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201508-529OC"},{"key":"2026010801351191000_67.1.2500400.47","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.resinv.2024.08.009","article-title":"Assessment of health-related quality of life in patients with nontuberculous mycobacterial pulmonary disease: a comprehensive review","volume":"62","author":"Kawahara","year":"2024","journal-title":"Respir Investig"},{"key":"2026010801351191000_67.1.2500400.48","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1513\/AnnalsATS.202107-765OC","article-title":"Time to positive culture detection predicts Mycobacterium avium pulmonary disease severity and treatment initiation","volume":"19","author":"Edwards","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"2026010801351191000_67.1.2500400.49","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12879-022-07250-4","article-title":"Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion","volume":"22","author":"Mingora","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2026010801351191000_67.1.2500400.50","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.chest.2021.08.046","article-title":"Mycobacterium Growth Indicator Tube time-to-positivity can serve as an early biomarker of treatment response in Mycobacterium avium complex pulmonary disease","volume":"161","author":"Danho","year":"2022","journal-title":"Chest"},{"key":"2026010801351191000_67.1.2500400.51","doi-asserted-by":"crossref","first-page":"884446","DOI":"10.3389\/fmed.2022.884446","article-title":"Clinical characteristics and mortality of non-tuberculous mycobacterial infection in immunocompromised vs. immunocompetent hosts","volume":"9","author":"Chai","year":"2022","journal-title":"Front Med"},{"key":"2026010801351191000_67.1.2500400.52","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2019.PA2928"},{"key":"2026010801351191000_67.1.2500400.53","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/18.5.736"},{"key":"2026010801351191000_67.1.2500400.54","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01636-2018"},{"key":"2026010801351191000_67.1.2500400.55","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00834-19"},{"key":"2026010801351191000_67.1.2500400.56","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00770-16"},{"key":"2026010801351191000_67.1.2500400.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.11.038"},{"key":"2026010801351191000_67.1.2500400.58","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa415"},{"key":"2026010801351191000_67.1.2500400.59","first-page":"e40993","article-title":"A 40-year-old female with Mycobacterium abscessus successfully treated with a dual beta-lactam combination","volume":"15","author":"Moguillansky","year":"2023","journal-title":"Cureus"},{"key":"2026010801351191000_67.1.2500400.60","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00098-20"},{"key":"2026010801351191000_67.1.2500400.61","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jiae601","article-title":"Imipenem pharmacokinetics\/pharmacodynamics in preclinical hollow fiber model, dose-finding in virtual patients, and clinical evidence of efficacy for Mycobacterium abscessus lung disease","volume":"231","author":"Singh","year":"2024","journal-title":"J Infect Dis"},{"key":"2026010801351191000_67.1.2500400.62","doi-asserted-by":"crossref","first-page":"02052-16","DOI":"10.1128\/AAC.02052-16","article-title":"Clofazimine-containing regimen for the treatment of Mycobacterium abscessus lung disease","volume":"61","author":"Yang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026010801351191000_67.1.2500400.63","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00586-7"},{"key":"2026010801351191000_67.1.2500400.64","doi-asserted-by":"crossref","first-page":"065","DOI":"10.23937\/2378-3516\/1410065","article-title":"Effects of chest physical therapy in patients with non-tuberculous mycobacteria","volume":"4","author":"Basavaraj","year":"2017","journal-title":"Int J Respir Pulm Med"},{"key":"2026010801351191000_67.1.2500400.65","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02143-2018"},{"key":"2026010801351191000_67.1.2500400.66","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-022-02109-5"},{"key":"2026010801351191000_67.1.2500400.67","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00629-2017"},{"key":"2026010801351191000_67.1.2500400.68","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.chest.2022.08.2228","article-title":"Gastroesophageal reflux disease increases susceptibility to nontuberculous mycobacterial pulmonary disease","volume":"163","author":"Kim","year":"2023","journal-title":"Chest"},{"key":"2026010801351191000_67.1.2500400.69","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-1906"},{"key":"2026010801351191000_67.1.2500400.70","doi-asserted-by":"publisher","DOI":"10.1093\/JAC\/DKAA110"},{"key":"2026010801351191000_67.1.2500400.71","doi-asserted-by":"crossref","first-page":"e0114422","DOI":"10.1128\/aac.01144-22","article-title":"Clofazimine inhalation suspension demonstrates promising toxicokinetics in canines for treating pulmonary nontuberculous mycobacteria infection","volume":"67","author":"Kunkel","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026010801351191000_67.1.2500400.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.05.003"},{"key":"2026010801351191000_67.1.2500400.73","doi-asserted-by":"publisher","DOI":"10.1378\/chest.15-0543"},{"key":"2026010801351191000_67.1.2500400.74","doi-asserted-by":"crossref","first-page":"638306","DOI":"10.3389\/fmed.2021.638306","article-title":"Role of clofazimine in treatment of Mycobacterium avium complex","volume":"8","author":"Nasiri","year":"2021","journal-title":"Front Med"},{"key":"2026010801351191000_67.1.2500400.75","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2665-5"},{"key":"2026010801351191000_67.1.2500400.76","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201307-231OC"},{"key":"2026010801351191000_67.1.2500400.77","doi-asserted-by":"crossref","first-page":"e00011-18","DOI":"10.1128\/AAC.00011-18","article-title":"Amikacin inhalation as salvage therapy for refractory nontuberculous mycobacterial lung disease","volume":"62","author":"Jhun","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026010801351191000_67.1.2500400.78","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/jac\/dkad372","article-title":"Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis","volume":"79","author":"Omar","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026010801351191000_67.1.2500400.79","unstructured":"Janssen Pharmaceutical KK . A study of bedaquiline administered as part of a treatment regimen with clarithromycin and ethambutol in adult patients with treatment-refractory Mycobacterium avium complex-lung disease (MAC-LD). 2025. https:\/\/clinicaltrials.gov\/study\/NCT04630145 Date last accessed: 20 March 2025."},{"key":"2026010801351191000_67.1.2500400.80","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2007.087999"},{"key":"2026010801351191000_67.1.2500400.81","unstructured":"Andrejak C , V\u00e9ziris N , Lescure F-X , et al. CaMoMy trial: a prospective randomized clinical trial to compare six-months sputum conversion rate with a clarithromycin or moxifloxacin containing regimen in patients with a M. xenopi pulmonary infection: intermediate analysis. Am J Respir Crit Care Med 2106; 193: A3733. doi:10.1164\/ajrccm-conference.2016.193.1_MeetingAbstracts.A3733"},{"key":"2026010801351191000_67.1.2500400.82","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks421"},{"key":"2026010801351191000_67.1.2500400.83","doi-asserted-by":"crossref","first-page":"e0205123","DOI":"10.1128\/spectrum.02051-23","article-title":"Clinical characteristics and treatment outcomes of Mycobacterium fortuitum pulmonary disease","volume":"11","author":"Kim","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2026010801351191000_67.1.2500400.84","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s41030-022-00210-y","article-title":"Phage therapy for nontuberculous mycobacteria: challenges and opportunities","volume":"9","author":"Hatfull","year":"2023","journal-title":"Pulm Ther"},{"key":"2026010801351191000_67.1.2500400.85","unstructured":"National Jewish Health . Mycobacteriophage treatment of non-tuberculosis mycobacteria (POSTSTAMP). 2024. https:\/\/clinicaltrials.gov\/study\/NCT06262282 Date last accessed: 20 March 2025."}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00400-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:35:21Z","timestamp":1767864921000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00400-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1183\/13993003.00400-2025"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00400-2025","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}